KAM
IOVA icon

Kazazian Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Kazazian Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,400
Closed -$84.4K – 73
2024
Q4 		$84.4K Buy
+11,400
New +$106K 0.06% 58
2019
Q3 		– Sell
-8,988
Closed -$220K – 63
2019
Q2 		$220K Sell
8,988
-1,167
-11% -$17.6K 0.26% 55
2019
Q1 		$97K Sell
10,155
-3,500
-26% -$34K 0.13% 57
2018
Q4 		$121K Buy
+13,655
New +$132K 0.16% 59

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Kazazian Asset Management's IOVA Position: Q1 2025 in Review

Kazazian Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 11,400 shares — an estimated $84.4K sold.

Kazazian Asset Management first reported a position in IOVA in Q4 2018 and held it in 4 quarters. The position peaked at $220K in Q2 2019. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Kazazian Asset Management reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 11,400 Iovance Biotherapeutics shares in Q1 2025, an estimated $84.4K.
  • Kazazian Asset Management first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 4 quarters.
  • Kazazian Asset Management's Iovance Biotherapeutics position peaked at $220K in Q2 2019.
  • 302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Kazazian Asset Management's 13F filing for Q1 2025, filed 9 May 2025.